Alembic Pharma shares touch all-time high after Q1 net profit surges over 11% YoY

Alembic Pharma's net profit in Q1 grew 11.69% year-on-year to ₹134.71 crore, compared to ₹120.6 crore reported in the corresponding period of last year. On a quarter-on-quarter basis, the net profit, however, declined 24.4% from ₹178.21 crore in Q4FY24.

The company’s net profit margin stood at 8.61% in the June quarter, compared to 8.11% a year ago.

The drug maker’s revenue from operations jumped 5.08% to ₹1561.73 crore in the June quarter compared to ₹1486.15 crore in Q1FY24. On a quarter-on-quarter basis, the company’s revenue from operations declined 2.94% from ₹1516.98 crore in the last quarter of FY24.

Alembic Pharma reported EBITDA (earnings before interest, tax, depreciation, and amortisation) of ₹239 crore in Q1.

The company's total revenue from India branded business grew 9% YoY to ₹572 crore in Q1 compared to ₹524 crore in the corresponding period of last fiscal.

Its revenue from the USA market surged 18% to ₹461 crore in the June quarter, compared to ₹390 crore in the same period last fiscal.

The company’s API business revenue, however, declined 15% to ₹259 crore in the June quarter compared to ₹305 crore in the year-ago period.

Commenting on the results, Shaunak Amin, MD of Alembic Pharmaceuticals Limited, said, “India's branded business continues to work on improving its execution ability, both in quality and scale. The Specialty and Animal health segment witnessed robust growth.

The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality.”

Alembic Pharmaceuticals shares pared its early morning gains and ended Thursday’s session at ₹1,216.80 apiece, down by 0.29% on NSE.